hat einer von euch infos bzw. kursziel
Top-News
techniclone
Beiträge:
6
Zugriffe: 1.872 / Heute: 1
Zugriffe: 1.872 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +48,05%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +46,01%
SPDR S&P U.S. Consumer Discretionary Select Sector UCITS ETF
Perf. 12M: +42,22%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +41,55%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +41,01%
in den US Boards gibt es "Vermutungen" dass Merck TCLN übernehmen möchte. Heute geht der Kurs gut ab, bis jetzt 20% hat soeben die 4 Dollar erreicht. Das ist immer noch entfernt vom High bei 16 im Frühjahr.
Sie haben außerdem ein Abkommen mit der UNI von Miami, was bedeutet, dass bestimmte Forschunegn für Medikamente abgekürtzt werden. Bin kein Mediziner, habe es so verstanden, dass es um ein Mittel gegen Krebs im Gehirn geht, das man an lebenden Personen ausprobieren kann mit Hilfe der Uni.
Ich habe kein Kursziel, denke aber, dass der Wert noch reichlich Potential hat.
Sie haben außerdem ein Abkommen mit der UNI von Miami, was bedeutet, dass bestimmte Forschunegn für Medikamente abgekürtzt werden. Bin kein Mediziner, habe es so verstanden, dass es um ein Mittel gegen Krebs im Gehirn geht, das man an lebenden Personen ausprobieren kann mit Hilfe der Uni.
Ich habe kein Kursziel, denke aber, dass der Wert noch reichlich Potential hat.
Hallo buzz
kannst du mir die adresse des boards nennen? habe gestern nachgekauft wegen analystentreffen vieler Biotechs und kann mein glück nicht fassen.
kannst du mir die adresse des boards nennen? habe gestern nachgekauft wegen analystentreffen vieler Biotechs und kann mein glück nicht fassen.
ich nehme in erster Linie Yahoo/Stockquotes/TCLN/ Messages. Von dort aus gibt es oft weitere Links, einfach mal ausprobieren. Einige sind ganz brauchbar, andere nicht, genau wie die Mitteilungen. Aber warum soll es in Amiland anders ein, als bei uns?
Viel Spaß beim Probieren.
Gruss
BUZZ
Viel Spaß beim Probieren.
Gruss
BUZZ
danke für die infos, buzz, hof ich mich mal revanchieren
das wird wohl der Grund für die 30% gestern gewesen sein.
TUSTIN, Calif.--(BUSINESS WIRE)--June 7, 2000--Techniclone Corporation (NASDAQ:TCLN), today announced that the U.S. Patent Office has issued U.S. Patent No. 6,071,491, that extends the usage of its Tumor Necrosis Technology (TNT) platform, as a diagnostic and imaging agent. The TNT technology is one of Techniclone's platform technologies for the treatment and diagnosis of solid tumors.
According to Steven King, Techniclone's Vice President of Technology and Product Development, "The issuance of this patent strengthens Techniclone's proprietary position in the use of Tumor Necrosis Therapy for use as a diagnostic and imaging agent. TNT is unique as a diagnostic agent because it is capable of detecting the existence of necrotic tissue which is found at the core of most solid tumors. We believe TNT has the potential to be an excellent imaging and diagnostic agent with broad applicability to different types of tumors."
Dr. John Bonfiglio, President and Chief Executive Officer, stated, "This patent further demonstrates the potential versatility of the TNT technology as both a diagnostic as well as therapeutic agent for solid tumor cancers. Techniclone is committed to expanding its intellectual property to estate in all of our platform technologies. This will allow us to execute our licensing and development strategies to ultimately provide relief to cancer patients and increase shareholder value."
According to Alan Epstein, M.D., Ph.D., Professor of Pathology at the University of Southern California, "We believe giving oncologists the ability diagnose and image multiple tumor types utilizing one single universal agent may be instrumental in affecting the positive outcome cancer therapy. We look forward to moving our imaging and diagnostic agent into human clinical testing in the future."
Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies". These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym(R) has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing
TUSTIN, Calif.--(BUSINESS WIRE)--June 7, 2000--Techniclone Corporation (NASDAQ:TCLN), today announced that the U.S. Patent Office has issued U.S. Patent No. 6,071,491, that extends the usage of its Tumor Necrosis Technology (TNT) platform, as a diagnostic and imaging agent. The TNT technology is one of Techniclone's platform technologies for the treatment and diagnosis of solid tumors.
According to Steven King, Techniclone's Vice President of Technology and Product Development, "The issuance of this patent strengthens Techniclone's proprietary position in the use of Tumor Necrosis Therapy for use as a diagnostic and imaging agent. TNT is unique as a diagnostic agent because it is capable of detecting the existence of necrotic tissue which is found at the core of most solid tumors. We believe TNT has the potential to be an excellent imaging and diagnostic agent with broad applicability to different types of tumors."
Dr. John Bonfiglio, President and Chief Executive Officer, stated, "This patent further demonstrates the potential versatility of the TNT technology as both a diagnostic as well as therapeutic agent for solid tumor cancers. Techniclone is committed to expanding its intellectual property to estate in all of our platform technologies. This will allow us to execute our licensing and development strategies to ultimately provide relief to cancer patients and increase shareholder value."
According to Alan Epstein, M.D., Ph.D., Professor of Pathology at the University of Southern California, "We believe giving oncologists the ability diagnose and image multiple tumor types utilizing one single universal agent may be instrumental in affecting the positive outcome cancer therapy. We look forward to moving our imaging and diagnostic agent into human clinical testing in the future."
Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies". These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents, (VTA). The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym(R) has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Bayer Schering Pharma Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 10 | NEUER MARKT dreht schon wieder nach unten !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! o.T. | AtomicBomb | AtomicBomb | 25.04.21 13:04 | ||
| 10 | Irrt die €uro weiter?Tops und Flops für nächste Wo | Peddy78 | buckstar | 30.11.06 20:06 | ||
2 | 46 | Schering | nuessa | Kicky | 19.05.06 09:18 | |
| 2 | 1 | Aktien-Newsletter ! | Waleshark | Guido | 23.02.06 07:37 | |
| +++Morgenbericht mit Terminen + Analysten 25.07.05 | eposter | 25.07.05 08:55 |
